Kura Oncology announced preliminary data from the FIT-001 clinical trial showing that darlifarnib combined with cabozantinib demonstrated a 44% objective response rate and 94% disease control rate in cabozantinib-pretreated clear cell renal cell carcinoma patients. The combination showed tumor shrinkage in 75% of patients with durable treatment durations up to 56 weeks and a manageable safety profile, suggesting potential to overcome resistance to prior cabozantinib therapy.

Kura Oncology granted nonstatutory stock options to purchase 153,750 shares to six new employees on April 1, 2026, with an exercise price of $8.34 per share. The options vest over four years with 25% vesting after one year and the remainder vesting monthly over 36 months, subject to continued employment.

Multiple biotech companies are advancing innovative immunotherapy and targeted treatments for blood cancers, with significant clinical trial progress and FDA approvals in acute myeloid leukemia (AML) and related hematologic conditions.

Kura Oncology and Kyowa Kirin announced FDA approval of KOMZIFTI, a once-daily oral menin inhibitor for relapsed/refractory NPM1-mutated AML, which has been added to NCCN Guidelines as a recommended treatment option.

Kura Oncology presented preliminary clinical data at ESMO 2025 demonstrating promising results for its farnesyl transferase inhibitor (FTI) programs, showing potential in combination therapies for treating various cancer types with encouraging response rates.

Market report highlights emerging menin inhibitor drugs targeting high-risk acute leukemias, with over 15 drugs in clinical trials and potential market opportunity exceeding $400 million by 2028.

Multiple health care stocks experienced significant options trading activity, with various bullish and bearish signals across different companies in the sector.

Kura Oncology and Kyowa Kirin published pivotal clinical trial results for ziftomenib, an investigational menin inhibitor targeting NPM1-mutated acute myeloid leukemia (AML), showing promising response rates and potential for FDA approval in November 2025.

Kura Oncology and Kyowa Kirin announced positive pivotal data from the KOMET-001 Phase 2 trial of ziftomenib, an investigational menin inhibitor, in patients with relapsed/refractory NPM1-mutant acute myeloid leukemia. The data showed a 23% complete remission/complete remission with partial hematological recovery rate and a favorable safety profile.

Kura Oncology and Kyowa Kirin announced that the FDA has accepted their New Drug Application for ziftomenib, a menin inhibitor, for the treatment of adult patients with relapsed or refractory NPM1-mutant acute myeloid leukemia. The application has been granted Priority Review with a target action date of November 30, 2025.

Kura Oncology and Kyowa Kirin announced positive results from the KOMET-001 trial of ziftomenib, an investigational menin inhibitor, in relapsed/refractory NPM1-mutant acute myeloid leukemia. The data will be presented at the 2025 ASCO Annual Meeting.

Kura Oncology announced the publication of its KOMET-001 Phase 1 study results in The Lancet Oncology, demonstrating promising clinical activity and manageable toxicity of its investigational drug ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia (AML).